Biomarkers for Immuno-Oncology

Disease immunotherapy is the utilization of the safe framework to treat tumor. Immunotherapies can be ordered as dynamic, uninvolved or half and half. These methodologies abuse the way that growth cells frequently have atoms on their surface that can be distinguished by the resistant framework, known as tumor-related antigens, they are regularly proteins or different macromolecules (e.g. sugars).

Dynamic immunotherapy guides the resistant framework to assault tumor cells by focusing on TAAs. Latent immunotherapies upgrade existing against tumor reactions and incorporate the utilization of monoclonal antibodies, lymphocytes and cytokines.

  • Personalized Immunotherapy
  • Companion Diagnostics For Immunotherapy
  • Biomarkers to guide Immunotherapy
  • Clinical Trials for Cancer Immunotherapy

Related Conference of Biomarkers for Immuno-Oncology

June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 16-17, 2024

9th World Conference on Breast and Cervical Cancer

London, UK
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France
November 24-25, 2024

7th International Conference on Anti-Cancer Drugs

Vancouver, Canada

Biomarkers for Immuno-Oncology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in